ProcureTech in the Real World [Online Meetup]
ProcureTech in the Real World: Online Meetup
19th Feb 2025
ProcureTech in the Real World: Online Meetup
19th Feb 2025
Dr. Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a Barcelona-based biotech company developing next-generation gene-editing tools. With a background in molecular biology and clinical genetics, she brings over 15 years of experience in genetic therapy research across Europe,
“The reality is, we have a lot of CDMOs that don’t really know what they’re getting into” says Herman Bozenhardt Herman Bozenhardt, a pharmaceutical manufacturing consultant with decades of experience in facility design and operations, brings a wealth of knowledge
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030. However, their rapid rise raises important questions about resource allocation in pharmaceutical development and manufacturing, as well
“Treat them as a partner, not just a supplier. It’s a mindset you need to get into.” – Federica Fraschetti, MSD Federica Fraschetti, Associate Director of External Manufacturing at MSD, brings years of experience in the pharmaceutical industry and a
“Sustainability is no longer just a buzzword in the pharmaceutical industry. It’s a critical business imperative,” says Hywel Woolf, Global Sustainability Manager at Sharp Services. “ “We’re seeing it become a golden thread in who organizations are and what they
“Manufacturing network strategy is about connecting the dots and seeing the interconnectivity between different brands,” explains Daniel Hurni, Director of Manufacturing Network Strategy and Business Intelligence at Bristol Myers Squibb (BMS). Daniel Hurni brings years of life sciences expertise to
VIVUNT, has proudly announced the inauguration of its third manufacturing facility, dedicated to the production of sterile oncology drugs in both lyophilized and liquid vials. This state-of-the-art plant, located in León, Spain, leverages cutting-edge technology and adheres to stringent international
“The GLP-1 agonist market is seeing unprecedented growth, and we’re investing €900 million to capture a fair amount of that business,” says CordenPharma’s Dr Mimoun Ayoub, outlining the CDMO’s most ambitious expansion plan to date in response to surging demand
Jon Reed, Head of Strategic Business Planning at Recipharm, recently shared insights into the CDMO’s latest innovations and market strategies. Speaking to the PharmaSource podcast at CPHI Milan, Jon explains how Recipharm, one of the largest CDMOs in the industry
Help us find the most innovative and trusted suppliers in Pharma and Biotech.